INTRODUCTION

OBJECTIVE
Medication errors (ME) are defined as any preventable events that may cause or lead to inappropriate medication use or patient harm. ME received national attention in the National Action Plan for Adverse Drug Event Prevention, to drive prevention strategies for high-risk drug classes. ME can occur during steps of the medication process (Fig 1) . Through continued research, the incidence of errors and economic consequences can be further elucidated.
To understand the economic burden of MEs that lead to preventable adverse drug events (pADEs) in US hospitals.
METHODS
From a broader literature review on injectable ME in PubMed and Embase (2003-2014) , we identified eleven articles related to the incidence or economic impact of pADEs arising from all ME. A supplemental PubMed search identified four additional articles dating back to 1995. All cost estimates were converted into 2014 US dollars. Per Preventable ADE or ME Cost • Sources of medication error data range from institution specific, real time observations to national databases sourced from voluntary or mandatory reporting systems, leading to different coverage of MEs included in analysis and ultimately to different estimates • The method for reporting medication error data varied across studies, and denominators for calculation of rates include per inpatient day, per patient admission and per medication administration • There is a lack of concordance in the cost of MEs among the studies due to differences in study methodologies and reporting systems 
RESULTS
Drug Preparation
Conclusion
Limitation of Studies • Different study methodologies, definitions of MEs and the use of varying denominators in calculation of ME rates hamper the ability to make meaningful comparisons between studies and prepare consolidated estimates • Some studies relied on voluntary reporting which has inherent reporting bias. All methodologies have some limitations, particularly in the ability to capture near misses or no harm events • The majority of data regarding the economic impact of MEs is dated This literature review highlights the economic burden of ME in the US. Cost estimates varied considerably due to different definitions, study methodologies, and analytic scope. Given the emergence of preventable ADE harm reduction as a national priority, there is a need for updated research aimed at evaluating the economic impact of medication errors using standardized definitions for types of errors, their severity and their financial impact. 
